Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Acute nonlymphocytic leukemia

L-Asparaginase is used for the treatment of appropriate lymphoproliferative disorders in two clinical trials, L-asparaginase was used in combination with chemotherapy for the treatment of refractory acute nonlymphocytic leukemia in children (24) and adults (25). A moderate efficacy, attributable to the enzyme, was demonstrated in both trials. [Pg.308]

Compare the classification systems for acute lymphocytic leukemia (ALL) and acute nonlymphocytic leukemia (ANLL). [Pg.1397]

Acute leukemias are classified according to their cell of origin. Acute lymphocytic leukemia (ALL) arises from the lymphoid line. Acute nonlymphocytic leukemia (ANLL) or acute myelogenous leukemia (AML) arises from the myeloid line. [Pg.1397]

A O Alert and oriented ANLL Acute nonlymphocytic leukemia... [Pg.1553]

Ota, K. et al., Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults., Cancer Immunol. Immunother., 23, 5, 1986. [Pg.170]

Except for the treatment of acute nonlymphocytic leukemia, mitoxantrone therapy generally should not be given to patients with baseline neutrophil counts less than 1500 cells/mm. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving mitoxantrone. [Pg.2020]

Mitoxantrone also is used in combination with other medications for prostate cancer and acute nonlymphocytic leukemia in adults. [Pg.2021]

Mitoxantrone Novantrone Carcinoma of the prostate acute nonlymphocytic leukemia Cough, shortness of breath leukopenia or infection stomatitis/mucositis Gl problems [stomach pain, nausea, vomiting, diarrhea, Gl bleeding]... [Pg.574]

Animal carcinogen. Reasonably anticipated to be a human carcinogen and when used as a chemotherapeutic agent in combination with nitrogen mustard, a potent animal carcinogen, can result in acute nonlymphocytic leukemia.5 Adverse effects in 50-70% of... [Pg.512]

Treatment-induced tumors Since most antineoplastic agents are mutagens, neoplasms (for example, acute nonlymphocytic leukemia) may arise 10 or more years after the original cancer was cured. Treatment-induced neoplasms are especially a problem after therapy with alkylating agents (see p. 387). [Pg.389]

Studies to determine whether benzene causes solid tumors and hematological malignancies other than acute nonlymphocytic leukemia in humans have been suggested as a data need (Goldstein and Warren... [Pg.262]

Ratain MJ, Kaminer LS, Bitran JD, Larson RA, Le Beau MM, Skosey C, Purl S, Hoffman PC, Wade J, Vardiman JW, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987 70(5) 1412-17. [Pg.3467]

Adjuvant treatment with methyl-CCNU has been evaluated in 3633 patients with gastrointestinal cancer treated in nine randomized trials. Among 2067 patients treated with methyl-CCNU, 14 cases of acute nonlymphocytic leukemia (ANLL) occurred, whereas... [Pg.1659]

ANLL, acute nonlymphocytic leukemia APE, acute promyelocytic leukemia CEL, chronic lymphocytic leukemia CML, chronic myelogenous leukemia EGER, epidermal growth factor receptor CIST, gastrointestinal stromal tumor MoAB, monoclonal antibody NE-kB, nuclear factor-KB Ph+ ALL, Philadelphia chromosome-positive acute lymphocytic leukemia PCP, Pneumocystis carinii pneumonia WBC, white blood cell. [Pg.2317]

ANC absolute neutrophil count ANLL acute nonlymphocytic leukemia ara-C cytarabine... [Pg.2325]

ArUn Z, Case DC Jr, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990 4 177-183. [Pg.2509]

Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 1988 6 583-587. [Pg.2509]

Geller RB, Saral R, Pianadosi S, et al. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood 1989 73 2209-2218. [Pg.2509]

Cheson BD, Simon R. Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes a review of 20 years experience. Semin Oncol 1987 14 126-133. [Pg.2509]

Benzene 1986/1996 Sufficient O AH routes Acute nonlymphocytic leukemia Y (hematopoietic)... [Pg.412]

M. M. Hudson, G. V. Dahl, D. K. Kalwinsky, and C. H. Pui. Methotrexate plus 1-asparaginase—an active combination for children with acute nonlymphocytic leukemia. Cancer 65 2615 (1990). [Pg.256]

Mitoxantrone (Novantrone) is supplied for intravenous infusion. To induce remission in acute nonlymphocytic leukemia in adults, the drug is given in a daily dose of 12 mg/m for 3 days as a component of a regimen that also includes cytosine arabinoside. Mitoxantrone also is used in advanced hormone-resistant prostate cancer in a dose of 12 to 14 mg/m every 21 days. Mitoxantrone has been approved by the FDA for the treatment of late-stage, secondary progressive multiple sclerosis. [Pg.215]

Etoposide is used primarily in treatment of testicular tumors in combination with bleomycin and cispiatin, and in combination with cispiatin and ifosfamide for small-cell carcinoma of the lung. It also is active against non-Hodgkin s lymphomas, acute nonlymphocytic leukemia, and Kaposi s sarcoma associated with AIDS. Etoposide has a favorable toxicity profile for dose escalation in that its primary acute toxicity is myelosuppression. In combination with ifosfamide and carboplatin, it is frequently used for high-dose chemotherapy in total doses of 1500 to 2000 mg/m. ... [Pg.259]

Mitoxantrone (12 mg/m daily by IV infusion on days 1 to 3) is nsed as an initial treatment in combination with other approved drugs for acute nonlymphocytic leukemia (AML). [Pg.448]

Filgrastim is a granulocyte colony stimulating factor that may be administered to reduce depression of neutrophils (neutropenia) seen with cancer chemotherapeutics, particularly those used for acute nonlymphocytic leukemia. [Pg.279]

Two standard dosage schedules are recommended for administration of cytarabine ( cytosar-u, TARABINE PFS, Others) (1) rapid intravenous infusion of 100 mg/nf every 12 hours for 5—7 days or (2) continuous intravenous infusion of 100 to 200 mg/nP daily for 5-7 days. In general, children tolerate higher doses than do adults. Intrathecal doses of 30 mg/m every 4 days have been used to treat meningeal leukemia. The intrathecal administration of 50-70 mg of the liposomal formulation of cytarabine (depocyt) every 2 weeks seems to be equally effective as the every-4-day regimen. Conventional cytarabine is indicated for induction and maintenance of remission in acute nonlymphocytic leukemia and is useful in the treatment of other leukemias, such as ALL AML, and CML in the blast phase. Intrathecal cytarabine is indicated for meningeal leukemia. [Pg.877]

See other pages where Acute nonlymphocytic leukemia is mentioned: [Pg.159]    [Pg.439]    [Pg.1398]    [Pg.926]    [Pg.927]    [Pg.357]    [Pg.393]    [Pg.90]    [Pg.91]    [Pg.55]    [Pg.34]    [Pg.215]    [Pg.429]    [Pg.2362]    [Pg.1801]    [Pg.2324]    [Pg.229]    [Pg.159]    [Pg.31]    [Pg.277]    [Pg.259]    [Pg.861]   
See also in sourсe #XX -- [ Pg.151 , Pg.155 , Pg.158 ]



SEARCH



Leukemia acute

© 2024 chempedia.info